# Construction and validation of an anoikis-related prognostic model for lung adenocarcinoma based on bulk and single-cell transcriptomic data

**Authors:** Yanfeng Xue, Yao Wang, Tianhao Huang, Yingjun Dong, Xin Tong

PMC · DOI: 10.1371/journal.pone.0335788 · 2025-11-04

## TL;DR

This study creates a 7-gene model to predict survival in lung adenocarcinoma patients by analyzing how genes related to anoikis resistance affect tumor progression and immune response.

## Contribution

A novel 7-gene prognostic model for LUAD based on anoikis-related genes and validated using bulk and single-cell data.

## Key findings

- The 7-gene model accurately predicted 1- to 3-year survival rates in two LUAD cohorts with AUC values above 0.68.
- High TIMP1 expression in epithelial cells correlates with immunosuppressive tumor microenvironment and increased Treg cell activity.
- The model is associated with clinical features, immune infiltration, and tumor microenvironment remodeling.

## Abstract

Lung adenocarcinoma (LUAD) is a highly aggressive lung cancer with poor prognosis due to lack of reliable biomarkers. Resistance to anoikis drives tumor progression and metastasis. This study aims to develop and validate an anoikis-related prognostic model for LUAD. We employed univariate Cox regression analysis, LASSO regression, and random forest algorithms to identify anoikis-related genes (ARG) from bulk transcriptomic datasets, and establish a 7-gene prognostic signature, validated in two LUAD cohorts from GEO database. We evaluated immune infiltration, molecular functions, and genomic alterations between risk groups and analyzed single-cell RNA sequencing data. IHC and mIF validated TIMP1 expression and its interaction with Treg cells. We developed a 7-gene prognostic model (LDHA, PLK1, TRAF2, ITGB4, SLCO1B3, TIMP1, ZEB2) using machine learning to predict survival in LUAD patients. The model accurately predicted 1-year survival rates (GSE31210: AUC = 0.805; GSE30219: AUC = 0.787), 2-year survival rates (GSE31210: AUC = 0.769; GSE30219: AUC = 0.681), and 3-year survival rates (GSE31210: AUC = 0.695; GSE30219: AUC = 0.735) and correlated with clinical features, immune infiltration, and tumor microenvironment (TME) remodeling. Single-cell sequencing data showed that LUAD patients exhibited an immunosuppressive TME phenotype, which was exacerbated by high TIMP1 expression in epithelial cells, promoting Treg cell activity. The 7-gene ARG prognostic model established in this study shows promising potential as a clinically applicable tool for decision-making.

## Linked entities

- **Genes:** LDHA (lactate dehydrogenase A) [NCBI Gene 3939], PLK1 (polo like kinase 1) [NCBI Gene 5347], TRAF2 (TNF receptor associated factor 2) [NCBI Gene 7186], ITGB4 (integrin subunit beta 4) [NCBI Gene 3691], SLCO1B3 (solute carrier organic anion transporter family member 1B3) [NCBI Gene 28234], TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076], ZEB2 (zinc finger E-box binding homeobox 2) [NCBI Gene 9839]
- **Diseases:** lung adenocarcinoma (MONDO:0005061)

## Full-text entities

- **Genes:** SLCO1B3 (solute carrier organic anion transporter family member 1B3) [NCBI Gene 28234] {aka HBLRR, LST-2, LST-3TM13, LST3, OATP-8, OATP1B3}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, ITGB4 (integrin subunit beta 4) [NCBI Gene 3691] {aka CD104, GP150, JEB5A, JEB5B}, ZEB2 (zinc finger E-box binding homeobox 2) [NCBI Gene 9839] {aka HSPC082, SIP-1, SIP1, SMADIP1, ZFHX1B}, TRAF2 (TNF receptor associated factor 2) [NCBI Gene 7186] {aka MGC:45012, RNF117, TRAP, TRAP3}, PLK1 (polo like kinase 1) [NCBI Gene 5347] {aka PLK, STPK13}
- **Diseases:** lung cancer (MESH:D008175), LUAD (MESH:D000077192), tumor (MESH:D009369), metastasis (MESH:D009362)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12585065/full.md

---
Source: https://tomesphere.com/paper/PMC12585065